NCLAT: IRP Has Authority to Take Possession of Assets Owned by Corporate Debtor  ||  NCLAT: NCLT Can Direct Forwarding a Copy of its Order to Relevant Statutory Authorities  ||  Delhi HC: Centre to Expedite Process of Accessibility Features in OTT platforms for PwDs  ||  Delhi HC: Once Worker Provides Testimony Under Oath ‘Burden of Proof’ Shifts on Employer  ||  SC: There Cannot be Discrimination in Matter of Payment of Pension to Retired Judges  ||  SC: India is Not a Dharamshala that Can Entertain Foreign Nationals from All Over  ||  SC: Can Quash Domestic Violence Act Complaints Under Section 482 of CrPC  ||  Supreme Court: Can’t Use Statement of One Accused against Another  ||  SC: Inclusion of Name in Draft NRC Cannot Annul Foreigners Tribunal’s Declaration as Non-Citizen  ||  Supreme Court: Minimum Practice of 3 Years Mandatory to Enter Judicial Service    

Roche Products v. Drugs Controller General of India and ors - (High Court of Delhi) (25 Apr 2016)

Delhi High Court to delve into Drug Controller irregularities

Civil

The Delhi High Court deferred a dispute regarding the development, classification and promotion of bio-similar drugs to 2 June 2016. Brought by Roche Products, the plaint raised concerns about irregularities by the Drug Controller General of India in granting approval to Biocon Limited and Mylan Pharmaceuticals for a bio-similar drug in five days - a process which usually takes much longer than that due to deliberation by three separate bodies, before it reaches the DCGI. The drug in question is Trastuzumab, used for treatment of breast cancer.

The Court accepted Roche’s arguments, ruling that “approvals…are not on the basis of the adherence of the Guidelines of 2012 and rules framed”. However, final finding would be arrived at upon completion of trial. The Defendants were allowed to continue manufacturing and marketing their drug claiming bio-similarity with Roche’s drug, but with certain provisos on indication used on packaging.

Tags : TRASTUZUMAB   BIO-SIMILAR   DCGI   ROCHE  

Share :        

Disclaimer | Copyright 2025 - All Rights Reserved